Advertisement

Topics

GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

20:43 EDT 12 Aug 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Pivotal trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity GI Dynamics Inc. (ASX:GID): • Primary Endpoint ...

Other Sources for this Article

Investor Relations
United States:
GI Dynamics Inc.
Janell Shields, +1 781-357-3280
investor@gidynamics.com

NEXT ARTICLE

More From BioPortfolio on "GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...